Skip to content

Frontotemporal Dementia Genetic Study

Frontotemporal Dementia Genetic Study - FTD-GEN

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57826
Enrollment
100
Registered
2024-10-23
Start date
2024-10-01
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frontotemporal dementia

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The participant must be 18 years old or older. • The participant must be a member of a family with a known pathogenic mutation in any of the genes causing FTD.An affected member is one who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum. o An at-risk member is one who is a first-degree relative of a family member affected with the disease. o Pathogenicity of a mutation is defined by those included within the GENF Ilist of FTD mutations. If a novel mutation is discovered that is likely to be pathogenic and has not yet been included within the FTD mutation database then the GENFI Genetics Core will decide on inclusion. Please send an email to the GENFI Trials Team at genfi@ucl.ac.uk. o A pathogenic C9orf72 expansion is defined as greater than 30 repeats. Intermediate expansions are not considered pathogenic. o Participants from one of the small number of families around the world in which 2 (or more) pathogenic mutations have been found should not be included in GENFI. • If the participant is demented or cognitively impaired there must be an available caregiver that can escort them. • The participant must have an identified informant. • The participant must be fluent in the language of their country of assessment.

Exclusion criteria

Exclusion criteria: Participants from one of the small number of families around the world in which 2 (or more) pathogenic mutations have been found. Participants with another medical or psychiatric illness that would interfere in completing assessments; participant is pregnant.

Design outcomes

Primary

MeasureTime frame
-cognitive functioning as objectified by MMSE and neuropsychological examination. -concentration of neurofilament light as determined in cerebrospinal fluid

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)